Type, timing, and patient characteristics associated with immune-related adverse event development in patients with advanced solid tumors treated with immune checkpoint inhibitors.Qian Qin, Che‐Kai Tsao, William Oh et al.|Journal of Clinical Oncology|2020Cited by 16
Smoking status and immunotherapy outcomes in smoking-associated cancers.Tomi Jun, Che‐Kai Tsao, Teja Ganta et al.|Journal of Clinical Oncology|2020Cited by 3
Type, timing, and risk factors associated with immune-related adverse event development in patients with advanced genitourinary cancers treated with immune checkpoint inhibitor.Qian Qin, Che‐Kai Tsao, Vaibhav G. Patel et al.|Journal of Clinical Oncology|2020Cited by 2
Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors.Vaibhav G. Patel, Che‐Kai Tsao, Qian Qin et al.|Journal of Clinical Oncology|2020Cited by 2
Characterizing patterns of disease progression in patients with genitourinary cancers treated with immune checkpoint inhibitors.Vaibhav G. Patel, Che‐Kai Tsao, Qian Qin et al.|Journal of Clinical Oncology|2020Cited by 1